Cookie Preference

This website uses cookies to improve user experience. Please select an option.  Privacy Policy

No cookies except for those necessary for technical reasons are set.


HKI and partners receive IQ Innovation Award for novel antibiotic against tuberculosis

This year’s innovation prize from the Metropolregion Mitteldeutschland goes to a team that has brought a novel anti-tuberculosis compound all the way from basic research to clinical studies – largely funded by public grants. The winners are Dr Florian Kloß from the Leibniz Institute for Natural Product Research and Infection Biology – Hans-Knoell-Institute (HKI), Dr Julia Dreisbach from the Ludwig-Maximilians-Universität München (LMU) and Dr Uwe Müller, CEO of HAPILA GmbH.

The antibiotic candidate identified at HKI has a new and unique mode of action with strong potential to combat tuberculosis caused by multidrug-resistant pathogens. Phase I trials have successfully been completed, and a phase II study is currently being prepared.

Ascenion, the HKI’s technology transfer partner, has managed all IP-relevant aspects of the project throughout the years and helped structure all partnership agreements.

Further information:
See HKI’s press release (German)